Clinical benefit of PD-1/PD-L1 inhibitors for poor performance status patients with advanced non-small cell lung cancer
The benefit of programmed cell death protein-1 (PD-1)/programmed cell death protein ligand-1 (PD-L1) inhibitors remains unclear in non-small cell lung cancer (NSCLC) patients with poor performance status (PS). In the current multi-centre retrospective cohort study, advanced or recurrent NSCLC patients treated with PD-1/PD-L1 inhibitors were enrolled. Of the 219 patients enrolled, 44 had PS 2-4. The objective response rate (ORR) of patients with PS 2-4 in 1<sup>st</sup> line was 33%. Among 1<sup>st</sup> line group, median progression-free survival (PFS) in patients with PS 2 was significantly longer compared to that in patients with PS 3-4 (15.3 months vs. 0.9 months, P = 0.039, Log-rank test). Among previously treated patients, the ORR of patients with PS 2-4 was only 4%, and PFS and overall survival was poor even in patients with PS 2. PD-1/PD-L1 inhibitors can be an option for PS 2 NSCLC patients in 1<sup>st</sup> line setting.
Authors
- Koji Sakamoto (ORCID: https://orcid.org/0000-0002-1794-576X)
- Ichidai Tanaka (ORCID: https://orcid.org/0000-0002-5517-0598)
- Shutaro Hori (ORCID: https://orcid.org/0000-0001-9213-0758)
- Yasuhiro Kondoh (ORCID: https://orcid.org/0000-0001-7456-5459)
- Sachiko Ozone (ORCID: https://orcid.org/0000-0003-0583-2917)
- Taro Tanaka (ORCID: https://orcid.org/0000-0002-5085-0439)
- Masaki Matsuo
- Tomoki Kimura (ORCID: https://orcid.org/0000-0001-9745-3329)
- Naozumi Hashimoto (ORCID: https://orcid.org/0000-0003-2337-629X)
- Reiko Matsuzawa
- Masahiro Morise (ORCID: https://orcid.org/0000-0001-6576-3349)
- Junji Koyama (ORCID: https://orcid.org/0000-0003-2958-7442)
- Akihiro Matsushita
- Koichiro Shima (ORCID: https://orcid.org/0000-0002-1315-4565)
- Shuichi Asano (ORCID: https://orcid.org/0000-0002-8293-3992)
Institutions
- Fujita Health University (JP)
- Chubu Rosai Hospital (JP)
- Nagoya Ekisaikai Hospital (JP)
- Chukyo Hospital (JP)
- Tosei General Hospital (JP)
- Nagoya University (JP)
Publication Details
- Journal
- Journal of Chemotherapy
- Published
- 2025-03-24
- DOI
- https://doi.org/10.1080/1120009x.2025.2481349
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00